Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/4/2017
SIETES contiene 91761 citas

 
 
 1 a 20 de 2099 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Schick A, Miller KL, Lanthier M, Pan GD, Nardinelli C. Evaluation of pre-marketing factors to predict post-marketing boxed warnings and safety withdrawals. Drug Saf 2017:24 de marzo. [Ref.ID 101505]
2. Cita con resumen
Anónimo. Crisaborole (Eucrisa) for atopic dermatitis. The Medical Letter on Drug and Therapeutics Bulletin 2017;59:34-5. [Ref.ID 101487]
3. Cita con resumen
Anónimo. FDA pushes back on Trump’s claims of slow drug reviews. DIA Daily 2017:8. [Ref.ID 101452]
5. Cita con resumen
Anónimo. Pembrolizumab (Keytruda) for first-line treatment of metastatic NSCLC. Med Lett Drugs Ther 2017;59:22-3. [Ref.ID 101421]
6. Cita con resumen
Anónimo. Lixisenatide for type 2 diabetes. Med Lett Drugs Ther 2017;59:19-21. [Ref.ID 101420]
7.Tiene citas relacionadas Cita con resumen
Wong J, Motulski A, Abrahamowicz M, McGill J, Eguale T, Buckeridge DL, Tamblyn R. Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system. BMJ 2017;356:j603. [Ref.ID 101417]
8.Tiene citas relacionadas Cita con resumen
Morales DR, Guthrie B. Off-label prescribing of antidepressants. BMJ 2017;356:j849. [Ref.ID 101416]
9. Cita con resumen
McGettigan P, Ferner RE. PCSK9 inhibitors for hypercholesterolaemia. BMJ 2017;356:j188. [Ref.ID 101397]
10.Enlace a cita original
Zarin DA, Tse T, Williams RJ, Rajakannan T. Update on trial registration 11 years after the ICMJE policy was established. N Engl J Med 2017;376:381-91. [Ref.ID 101395]
11. Cita con resumen
Spelsberg A , Prugger C , Doshi P , Ostrowski K , Witte T , Hüsgen D , Keil U , for the Working Group on Health and Working Group on Freedom of Information Transparency International Deutschland eV. Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies. BMJ 2017;356:j337. [Ref.ID 101390]
12. Cita con resumen
Anónimo. Brazil issues first license for sale of cannabis-based drug. DIA Daily 2017:1. [Ref.ID 101349]
13.Enlace a cita original Cita con resumen
Mielke J, Jilma B, Jones B. Clinical trials for authorized biosimilars in the European Union: a systematic review. Br J Clin Pharmacol 2016;82:1444-57. [Ref.ID 101025]
14.Enlace a cita original
Anónimo. Armodafinil for sleep disorders. Australian Prescriber 2016;39:221. [Ref.ID 101022]
15. Cita con resumen
Anónimo. FDA approves fewest new drugs last year since 2010. DIA Daily 2017:2. [Ref.ID 101018]
16. Cita con resumen
Erviti López J, Saiz Fernández LC, Garjón Parra J. Fiabilidad de los ensayos clínicos. El peligroso camino de la desregulación de los medicamentos. Med Clin (Barc) 2016;147:554-7. [Ref.ID 101012]
20. Cita con resumen
Anónimo. FDA approves diabetes drug. DIA Daily 2016:2. [Ref.ID 100975]
Seleccionar todas
 
 1 a 20 de 2099 siguiente >>